Suppliers / Zhejiang Jinhua Conba Bio-Pharm

Zhejiang Jinhua Conba Bio-Pharm

China Updated 9 July 2026

Zhejiang Jinhua Conba Bio-Pharm is an API manufacturer based in China. It holds 7 active US drug master files across a filed portfolio of 7 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 28 April 2025 as VAI.

7
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
5 of 5 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 28 April 2025 VAI US FDA
  • 13 December 2019 NAI US FDA
  • 26 January 2018 VAI US FDA
  • 30 October 2015 VAI US FDA
  • 23 January 2013 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3003663281

What they file, and where

Molecule Regulators Docs
Acetylcysteine US FDA 1
Aripiprazole US FDA 1
Azithromycin US FDA 1
Dabigatran Etexilate US FDA 1
Omeprazole US FDA 1
Rivaroxaban US FDA 1
Tazobactam US FDA 1

Also appears on these molecule pages

Acetylcysteine API Azithromycin API Tazobactam API Omeprazole API Rivaroxaban API Aripiprazole API Dabigatran Etexilate API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Questions about Zhejiang Jinhua Conba Bio-Pharm

Does Zhejiang Jinhua Conba Bio-Pharm hold a US DMF or a CEP?
Zhejiang Jinhua Conba Bio-Pharm holds 7 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Zhejiang Jinhua Conba Bio-Pharm FDA-registered?
One site operated by Zhejiang Jinhua Conba Bio-Pharm carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Zhejiang Jinhua Conba Bio-Pharm's last inspection go?
The most recent inspection on record closed on 28 April 2025 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 5 inspections are on file.
Where does Zhejiang Jinhua Conba Bio-Pharm manufacture?
1 registered site is on record, in China (China). Every site is listed on this page with the register it came from.
What does Zhejiang Jinhua Conba Bio-Pharm make?
7 molecules are on record against Zhejiang Jinhua Conba Bio-Pharm, including Acetylcysteine, Aripiprazole, Azithromycin and Dabigatran Etexilate. Each links through to that molecule's full manufacturer list.
Which regulators recognise Zhejiang Jinhua Conba Bio-Pharm's GMP?
Current GMP certificates are on record from US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Zhejiang Jinhua Conba Bio-Pharm comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 28 April 2025.

Comparable suppliers

Shandong Anxin Pharmaceutical shares 2 molecules Imexpharm shares 2 molecules Apitoria Pharma shares 1 molecule Alembic Pharmaceuticals shares 1 molecule Jubilant Biosys shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates